Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Q4 Revenues Jump 11 Percent on Strong Gene-Screening Business Growth

NEW YORK, Jan. 27 (GenomeWeb News) - Spurred by revenue in its Life and Analytical Sciences division, PerkinElmer's total receipts jumped 11 percent in the fourth quarter of 2004.

 

Total company revenue for the three months ended Dec. 31 shot up to $478 million from $431.8 million in the year-ago period. The Life and Analytical Sciences division saw revenue grow to $311 million in the fourth qurter of 2004 from $290 million in the same period last year -- a rise of 6.8 percent.

 

The company attributed the division's growth during the quarter to "double digit" revenue growth in its genetic-screening, -service and environmental businesses.

 

PerkinElmer's R&D expenses for the fourth quarter of 2004 were up $4.7 million to $23.6 million.

 

Net income grew 27 percent, as PerkinElmer reported $37.9 million for the fourth quarter of 2004, compared to $27.9 million year-over-year.

 

PerkinElmer had around $197.5 million in cash and equivalents as of Jan. 2.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more